The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children.
10.3346/jkms.2015.30.5.612
- Author:
Hyo Jin KWON
1
;
Soo Young LEE
;
Ki Hwan KIM
;
Dong Soo KIM
;
Sung Ho CHA
;
Dae Sun JO
;
Jin Han KANG
Author Information
1. Department of Pediatrics, The Catholic University of Korea College of Medicine, Seoul, Korea. kjhan@catholic.ac.kr
- Publication Type:Original Article ; Clinical Trial ; Research Support, Non-U.S. Gov't
- Keywords:
Live Attenuated Japanese Encephalitis Vaccine;
Immunogenicity;
Safety;
Children;
Clinical Trial
- MeSH:
Antibodies, Neutralizing/analysis/immunology;
Antibodies, Viral/analysis/immunology;
Antibody Formation;
Child, Preschool;
Cohort Studies;
Encephalitis, Japanese/*prevention & control;
Female;
Humans;
Infant;
Japanese Encephalitis Vaccines/*immunology;
Male;
Prospective Studies;
Vaccination;
Vaccines, Attenuated/*immunology
- From:Journal of Korean Medical Science
2015;30(5):612-616
- CountryRepublic of Korea
- Language:English
-
Abstract:
Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) in endemic areas. Although the live attenuated SA 14-14-2 JE vaccine (LAJEV) has been widely used since its introduction, the systemic data of LAJEV was very rarely available in Korea. We conducted the open-label, prospective cohort study to assess the immunogenicity and safety of this vaccine. Ninety subjects were enrolled, and LAJEV in a 2-dose primary series was given with a 12-month interval. Neutralizing antibody titers were measured before and after each vaccination, and active monitoring for adverse events was performed. After the first dose, 91.1% of subjects had seroprotection with a geometric mean titer (GMT) of 40.9. Seroprotection rate after the second dose was 97%, and GMT showed an increase of 6.5-fold. Most adverse events following immunization were self-limited, and no serious adverse events were reported until 42 days after each dose. The 2-dose administration of LAJEV in the primary immunization schedule appeared to be highly immunogenic and safe.
